darinaparsin: cytotoxic compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11683005 |
| CHEMBL ID | 3247378 |
| CHEBI ID | 94295 |
| SCHEMBL ID | 411358 |
| MeSH ID | M0504230 |
| Synonym |
|---|
| sglu1 |
| dmas(iii)g |
| zio-101-c |
| zinapar |
| darinaparsin |
| zio-101 |
| sp-02l |
| 69819-86-9 |
| D08898 |
| darinaparsin (jan/usan) |
| clarinaparsin |
| s-(dimethylarsino)glutathione |
| s-dimethylarsino-glutathione |
| zio101 |
| dimethylarsinous glutathione |
| dmas(iii)sg |
| s-(dimethylarsino)-glutathione |
| zio 101 |
| l-gamma-glutamyl-s-(dimethylarsanyl)-l-cysteinylglycine |
| unii-9xx54m675g |
| glycine, l-gamma-glutamyl-s-(dimethylarsino)-l-cysteinyl |
| darinaparsin [usan:inn] |
| 9xx54m675g , |
| BRD-K35723520-001-01-0 |
| glycine, l-.gamma.-glutamyl-s-(dimethylarsino)-l-cysteinyl- |
| darinaparsin [mi] |
| darinaparsin [usan] |
| darinaparsin [jan] |
| darinaparsin [who-dd] |
| darinaparsin [inn] |
| CHEMBL3247378 |
| SCHEMBL411358 |
| DTXSID80220108 |
| sp02 |
| s-dimethylarsino glutathione |
| s-dimethylarsinoglutathione |
| JGDXFQORBMPJGR-YUMQZZPRSA-N |
| CHEBI:94295 |
| glycine, l-gamma-glutamyl-s-(dimethylarsino)-l-cysteinyl- |
| BCP15637 |
| zio 101; zio101; zio-101 |
| Q27166111 |
| DB06179 |
| (s)-2-amino-5-(((r)-1-((carboxymethyl)amino)-3-((dimethylarsino)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid |
| (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-dimethylarsanylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid |
| l-gamma-glutamyl-s-(dimethylarsino)-l-cysteinyl-glycine |
| HY-14943 |
| AKOS040754941 |
Darinaparsin (Zio-101) is a novel organic arsenical compound of dimethylated arsenic conjugated to glutathione. It has encouraging clinical activity in relapsed/refractory T-cell lymphoma and Hodgkin lymphoma. Little is known about its mechanism of action.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Darinaparsin may therefore increase the therapeutic index of radiation therapy and has near term translational potential." | ( Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Knox, SJ; Li, X; Nolley, R; Peehl, DM; Reese, SW; Tian, J; Young, SR; Zhao, H, 2012) | 2.54 |
Darinaparsin treatment resulted in time- and dose-dependent cytotoxicity and apoptosis in all TCL and HL cell lines. Treatment results in higher intracellular arsenic accumulation when compared to As(2)O(3) treatment.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Darinaparsin treatment resulted in time- and dose-dependent cytotoxicity and apoptosis in all TCL and HL cell lines. " | ( The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. Bhalla, S; Crombie, J; Evens, AM; Gartenhaus, RB; Kandela, I; Mazar, A; Ravi, D; Sharma, J, 2014) | 2.14 |
| "Darinaparsin treatment results in higher intracellular arsenic accumulation when compared to As(2)O(3) treatment." | ( A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Colombo, M; Diaz, Z; Komarnitsky, PB; Kourelis, M; Mann, KK; Marcoux, S; Miller, WH, 2008) | 1.07 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " To our surprise DMA(III)(SG) effectively killed cells in the neighbor wells of the same multi-well dish, indicating that volatile toxic compounds generated from DMA(III)(SG) in the culture medium." | ( Cytotoxic effects of S-(dimethylarsino)-glutathione: a putative intermediate metabolite of inorganic arsenicals. Hirano, S; Kobayashi, Y, 2006) | 0.33 |
| "Although inorganic arsenite (As(III)) is toxic in humans, it has recently emerged as an effective chemotherapeutic agent for acute promyelocytic leukemia (APL)." | ( Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215). Himeno, S; Hirano, S; Kobayashi, Y; Kojima, C; Sakurai, MH; Sakurai, T; Waalkes, MP, 2006) | 0.33 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The development of orally bioavailable organic arsenic derivatives (OAD) offering improved toxicity profiles and better efficacy may expand the use of arsenic derivatives in hematologic malignancies and solid tumors." | ( Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Chen, YW; Freireich, E; Kantarjian, H; Quintás-Cardama, A; Verstovsek, S; Zingaro, R, 2008) | 0.62 |
| Class | Description |
|---|---|
| peptide | Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1130305 | Bacteriostatic activity against Klebsiella pneumoniae | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Biomolecules bearing the S- or SeAsMe2 function: amino acid and steroid derivatives. |
| AID1130304 | Bacteriostatic activity against Staphylococcus aureus 209 cultured in nutrient broth | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Biomolecules bearing the S- or SeAsMe2 function: amino acid and steroid derivatives. |
| AID1130298 | Toxicity in mouse allografted with mouse L1210 cells | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Biomolecules bearing the S- or SeAsMe2 function: amino acid and steroid derivatives. |
| AID1130303 | Bacteriostatic activity against Staphylococcus aureus 209 | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Biomolecules bearing the S- or SeAsMe2 function: amino acid and steroid derivatives. |
| AID1130297 | Carcinostatic activity against mouse L1210 cells allografted in mouse assessed as increase in survival at 100 mg/kg relative to control | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Biomolecules bearing the S- or SeAsMe2 function: amino acid and steroid derivatives. |
| AID1130301 | Carcinostatic activity against mouse L1210 cells allografted in mouse assessed as increase in life span at 500 mg/kg relative to control | 1979 | Journal of medicinal chemistry, May, Volume: 22, Issue:5 | Biomolecules bearing the S- or SeAsMe2 function: amino acid and steroid derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 6 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (27.27%) | 5.53% |
| Reviews | 2 (6.06%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||